Research programme: therapeutic antibody fragments - Cell Medica

Drug Profile

Research programme: therapeutic antibody fragments - Cell Medica

Alternative Names: DLX-1008; DLX-212; DLX-2201; DLX-2323/DLX2681; DLX-2751; DLX-2882/3003; DLX-521; DLX-903; DLX-903/1008

Latest Information Update: 24 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Delenex Therapeutics
  • Developer Cell Medica
  • Class Antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Anaplastic lymphoma kinase inhibitors; Interleukin 1 beta inhibitors; Interleukin 12 inhibitors; Interleukin 23 inhibitors; Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acne; Glioblastoma; Gout; Hidradenitis suppurativa; Inflammatory bowel diseases; Kaposi's sarcoma; Psoriasis; Pyoderma
  • No development reported Cancer; Neurological disorders; Skin disorders

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Kaposi sarcoma and Glioblastoma presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Switzerland
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top